Kalaris Therapeutics, Inc. (KLRS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.20 (+1.27%), Market cap $0.12B, 52-week low–high $2.27 ~ $10.98.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Financial statements, price targets, institutional (13F) holdings and related news for Kalaris Therapeutics, Inc. are updated in real time on BlackAll Trade.
Kalaris Therapeutics, Inc. trades at $3.20 (+1.27%). Real-time quotes and charts are available on BlackAll Trade.
Kalaris Therapeutics, Inc. has a market cap of about $0.12B.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-sta